#breastcancer #NICE #NHS #HEOR #Enhertu #AstraZeneca #DaiichiSankyo #Oncology #HER2lowbreastcancer #incurablebreastcancer #NICEFinaldraftguidance #reimbursement #metastaticbreastcancer #NICEcosteffectivenessthreshold #NICErecommendation #CancerDrugsFund #NHScommissioning
zurl.co/eYPtT
zurl.co/eYPtT
NICE finally backs Enhertu for HER2-low breast cancer
Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.
pharmaphorum.com
September 18, 2026 at 8:24 AM